Sanofi, OpenAI, Formation Bio announce AI drug development partnership

French phar­ma­ceu­ti­cal gi­ant Sanofi will work with the tech pow­er­house Ope­nAI and New York-based start­up For­ma­tion Bio to de­vel­op AI-pow­ered soft­ware in drug R&D, the three com­pa­nies an­nounced Tues­day.

The deal is the lat­est ex­am­ple of a tight­en­ing re­la­tion­ship be­tween drug­mak­ers and AI com­pa­nies, and the sec­ond ma­jor deal that Ope­nAI has made in the bio­phar­ma in­dus­try, af­ter an­nounc­ing a col­lab­o­ra­tion arrange­ment with Mod­er­na last month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.